Use of an RXR agonist in treating HER2+ cancers
US10966950B2 · kind B2 · utility
10Cited by
63References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 10, 2020 |
| Grant date | Apr 6, 2021 |
| Priority date | — |
| Expiry date | Jun 10, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/185
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.